ProCE Banner Activity

ExpressPoints
Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Slideset Download
Gain key clinical insights fast, with this short slideset from CCO on key considerations for recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Released: November 29, 2021

Expiration: November 28, 2022

No longer available for credit.

Share

Faculty

Asim V. Farooq

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Joann Kang

Joann Kang, MD

Associate Professor of Ophthalmology
Montefiore Medical Center/Albert Einstein College of Medicine
Director, Cornea and Refractive Surgery
Montefiore Medical Center
Bronx, New York

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Joann Kang, MD

Associate Professor of Ophthalmology
Montefiore Medical Center/Albert Einstein College of Medicine
Director, Cornea and Refractive Surgery
Montefiore Medical Center
Bronx, New York

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts